We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Review · September 15, 2021

Cabozantinib + Nivolumab as First-Line Treatment in Advanced RCC

Expert Review of Anticancer Therapy

 

Additional Info

Expert Review of Anticancer Therapy
Cabozantinib and Nivolumab as First-Line Treatment in Advanced Renal Cell Carcinoma
Expert Rev Anticancer Ther 2021 Aug 27;[EPub Ahead of Print], MG Vitale, C Nasso, M Oltrecolli, C Baldessari, M Fanelli, M Dominici, R Sabbatini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading